ArticleMarine drugs2016
Natural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors.
Article in Marine drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Alzheimer's Disease Protein Targets: Comprehensive Review and Future Directions.Current pharmaceutical design · 2025Review
- Microalgal bioactives as emerging nutritional regulators of apoptosis and neuroplasticity: targeting metabolic dysfunction in aging, neurodegenerative diseases, and cancer.Frontiers in pharmacology · 2025Review
- Determination of Potential Lead Compound fromInternational journal of molecular sciences · 2024Article
- Cyanometabolites: molecules with immense antiviral potential.Archives of microbiology · 2023Review
- Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease.Frontiers in aging neuroscience · 2023Review
- Biospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM) · 2023Review
- Review
- Natural Products from Plants and Algae for Treatment of Alzheimer's Disease: A Review.Biomolecules · 2022Review
- Alzheimer's Disease and Toxins Produced by Marine Dinoflagellates: An Issue to Explore.Marine drugs · 2022Review
- Tetrahydroimidazo[4,5-Pharmaceuticals (Basel, Switzerland) · 2021Article
- Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease.ChemistryOpen · 2021Article
- Phytoplankton of the Curonian Lagoon as a New Interesting Source for Bioactive Natural Products. Special Impact on Cyanobacterial Metabolites.Biomolecules · 2021Article
- Marine-Derived Compounds with Anti-Alzheimer's Disease Activities.Marine drugs · 2021Review
- Unlocking the Health Potential of Microalgae as Sustainable Sources of Bioactive Compounds.International journal of molecular sciences · 2021Review
- Development of a targeted HPLC-ESI-QqQ-MS/MS method for the quantification of sulfolipids from a cyanobacterium, selected leafy vegetables, and a microalgae species.Analytical and bioanalytical chemistry · 2021Article
- Bioassay-guided isolation of glycolipids from the seaweedResearch in pharmaceutical sciences · 2020Article
- Omics for Bioprospecting and Drug Discovery from Bacteria and Microalgae.Antibiotics (Basel, Switzerland) · 2020Review
- Monogalactosyldiacylglycerol and Sulfolipid Synthesis in Microalgae.Marine drugs · 2020Article
- Microalgae with Immunomodulatory Activities.Marine drugs · 2019Review
- Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis-A pilot study.Archives of oral biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, many new enzymes, like glutaminyl cyclase (QC), could be associated with pathophysiological processes and represent targets for many diseases, so that enzyme-inhibiting properties of natural substances are becoming increasingly important. In different studies, the pathophysiology connection of QC to various diseases including Alzheimer's disease (AD) was described. Algae are known for the ability to synthesize complex and highly-diverse compounds with specific enzyme inhibition properties. Therefore, we screened different algae species for the presence of QC inhibiting metabolites using a new "Reverse Metabolomics" technique including an Activity-correlation Analysis (AcorA), which is based on the correlation of bioactivities to mass spectral data with the aid of mathematic informatics deconvolution. Thus, three QC inhibiting compounds from microalgae belonging to the family of sulfolipids were identified. The compounds showed a QC inhibition of 81% and 76% at concentrations of 0.25 mg/mL and 0.025 mg/mL, respectively. Thus, for the first time, sulfolipids are identified as QC inhibiting compounds and possess substructures with the required pharmacophore qualities. They represent a new lead structure for QC inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.